GlaxoSmithKline LLC OMB112517

  • IRB Number: GlaxoSmithKline LLC OMB112517
  • Contact Name: Rachel O'Loughlin, RN
  • Phone: (585) 747-4555
  • Lead Researcher: Saad Jamshed, MD

Description

GlaxoSmithKline LLC OMB112517: A Phase III, open label, randomized, multicenter trial of Ofatumumab maintenance treatment versus no further treatment in subjects with relapsed Chronic Lymphocytic Leukemia (CLL) who have responded to induction therapy.